Unavailable
Unavailable
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/6/2025 | $10.00 | Neutral | Goldman |
| 7/19/2024 | $15.00 | Buy | Jefferies |
| 10/23/2023 | $13.00 → $9.00 | Neutral → Underperform | BofA Securities |
| 6/23/2023 | $11.00 | Equal Weight → Underweight | Barclays |
| 4/24/2023 | $11.00 | Overweight → Equal Weight | Barclays |
| 2/17/2023 | $16.00 → $14.00 | Outperform → Market Perform | BMO Capital Markets |
| 1/27/2023 | $13.00 → $15.00 | Hold → Buy | Jefferies |
| 11/10/2022 | $9.00 → $12.00 | Sell → Neutral | UBS |
4 - Viatris Inc (0001792044) (Issuer)
3 - Viatris Inc (0001792044) (Issuer)
4 - Viatris Inc (0001792044) (Issuer)
PITTSBURGH, Aug. 19, 2025 /PRNewswire/ -- Viatris Inc. (NASDAQ:VTRS), a global healthcare company, today announced the appointment of Andrew Enrietti as Chief Administrative and Transformation Officer. In this newly created role, Enrietti will oversee the company's Human Relations, Business Transformation, Information Technology, Information Security, Global Transportation and Security, and Global Workplaces and Real Estate functions. The consolidation of these areas centralizes leadership of the company's digital, cultural and structural transformation initiatives and is designed to accelerate the company's ongoing strategic evolution.
Approval is Another Milestone of Viatris' Ability to Successfully Develop Complex Generic Medicines Approval Granted with Competitive Generic Therapy Eligibility for 100mg/5mL and 200mg/10mL Strengths; Provides Eligibility for 180 Days of Exclusivity PITTSBURGH, Aug. 11, 2025 /PRNewswire/ -- Viatris Inc. (NASDAQ:VTRS), a global healthcare company, today announced the U.S. Food and Drug Administration (FDA) has approved Iron Sucrose Injection, USP, an intravenous iron replacement product used to treat iron deficiency anemia (IDA) in adult and pediatric patients (2 years of age and older) with chronic kidney disease (CKD). IDA is a common complication of CKD and is associated with a significa
Delivers Total Revenues Above Expectations Reflecting the Strength of our Execution and the Resilience of our Diversified Global BusinessPositive Results From Five Phase 3 Data Readouts This Year Reinforce Continued Momentum of Late-Stage Pipeline Returns More Than $630 Million of Capital to Shareholders Year-to-Date Including $350 Million in Share BuybacksReiterates 2025 Financial Guidance Ranges Across all Metrics and Expects to be in the Top Half of the Range for Total Revenues and Adjusted EPS [1]PITTSBURGH, Aug. 7, 2025 /PRNewswire/ -- Viatris Inc. (NASDAQ:VTRS) today reported strong second quarter 2025 financial results and reiterated its 2025 financial guidance ranges across all metri
SCHEDULE 13G - Viatris Inc (0001792044) (Subject)
10-Q - Viatris Inc (0001792044) (Filer)
SCHEDULE 13G/A - Viatris Inc (0001792044) (Subject)
4 - Viatris Inc (0001792044) (Issuer)
4 - Viatris Inc (0001792044) (Issuer)
4 - Viatris Inc (0001792044) (Issuer)
Goldman initiated coverage of Viatris with a rating of Neutral and set a new price target of $10.00
Jefferies resumed coverage of Viatris with a rating of Buy and set a new price target of $15.00
BofA Securities downgraded Viatris from Neutral to Underperform and set a new price target of $9.00 from $13.00 previously
PITTSBURGH, Aug. 19, 2025 /PRNewswire/ -- Viatris Inc. (NASDAQ:VTRS), a global healthcare company, today announced the appointment of Andrew Enrietti as Chief Administrative and Transformation Officer. In this newly created role, Enrietti will oversee the company's Human Relations, Business Transformation, Information Technology, Information Security, Global Transportation and Security, and Global Workplaces and Real Estate functions. The consolidation of these areas centralizes leadership of the company's digital, cultural and structural transformation initiatives and is designed to accelerate the company's ongoing strategic evolution.
PITTSBURGH, Aug. 5, 2025 /PRNewswire/ -- Viatris Inc. (NASDAQ:VTRS), a global healthcare company, today announced that David Simmons has been appointed as the newest member of Viatris' Board of Directors. Simmons has deep pharmaceutical industry experience, as well as extensive executive, board, and capital markets expertise. Prior to his current role as CEO of Caliber Holdings Corporation, Simmons served as Operating Partner of Hellman & Friedman, LLC, a leading private equity firm, as well as Chairman and CEO of PPD, Inc., a global contract pharmaceutical research organizati
PITTSBURGH, April 14, 2025 /PRNewswire/ -- Viatris Inc. (NASDAQ:VTRS) today announced that Hemanth J. Varghese has joined the Company as Chief Strategy Officer. Varghese will be a member of the Company's Executive Leadership Team. Varghese is an accomplished healthcare leader with more than 20 years of strategy, operations and corporate development experience. He brings broad experience leading growth initiatives and strategic transformations in diversified multi-national healthcare companies. Prior to joining Viatris, Varghese was President and Chief Operating Officer at Venu
Delivers Total Revenues Above Expectations Reflecting the Strength of our Execution and the Resilience of our Diversified Global BusinessPositive Results From Five Phase 3 Data Readouts This Year Reinforce Continued Momentum of Late-Stage Pipeline Returns More Than $630 Million of Capital to Shareholders Year-to-Date Including $350 Million in Share BuybacksReiterates 2025 Financial Guidance Ranges Across all Metrics and Expects to be in the Top Half of the Range for Total Revenues and Adjusted EPS [1]PITTSBURGH, Aug. 7, 2025 /PRNewswire/ -- Viatris Inc. (NASDAQ:VTRS) today reported strong second quarter 2025 financial results and reiterated its 2025 financial guidance ranges across all metri
PITTSBURGH, Aug. 5, 2025 /PRNewswire/ -- Viatris Inc. (NASDAQ:VTRS) today announced that on August 4, 2025, its Board of Directors declared a quarterly dividend of $0.12 per share for each issued and outstanding share of the Company's common stock. The dividend is payable on September 15, 2025, to shareholders of record as of the close of business on August 22, 2025. About Viatris Viatris Inc. (NASDAQ:VTRS) is a global healthcare company uniquely positioned to bridge the traditional divide between generics and brands, combining the best of both to more holistically address healthcare needs globally. With a mission to empower people worldwide to live healthier at every stage of life, we provi
PITTSBURGH, June 12, 2025 /PRNewswire/ -- Viatris Inc. (NASDAQ:VTRS) will report second quarter 2025 financial results on Thursday, August 7, 2025. Company executives will host a webcast at 8:30 a.m. ET on the same date to discuss the results. Investors and the general public are invited to listen to a live webcast of the call at investor.viatris.com or by calling 844.308.3344 or 412.317.1896 for international callers. A replay of the webcast also will be available on the website. About Viatris Viatris Inc. (NASDAQ:VTRS) is a global healthcare company uniquely positioned to br
SC 13G/A - Viatris Inc (0001792044) (Subject)
SC 13G/A - Viatris Inc (0001792044) (Subject)
SC 13G - Viatris Inc (0001792044) (Subject)